Sign in
TerminatedPhase 2

Pembro+Chemo in Brain Mets

Key facts

Who runs it
John L. Villano, MD, PhD
Where
Lexington, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
3 people enrolled
Started
19 May 2022
Ended
19 Dec 2023
Type of study
Interventional
Treatments tested
  • Pembrolizumab
  • Nab paclitaxel
  • Paclitaxel
  • Pemetrexed
  • Carboplatin
Record updated
31 October 2025
Why it stopped
Slow Accrual

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Non-small cell lunch cancer (NSLC) with untreated asymptomatic brain metastases
  • NSLC lacks oncogenic driver mutations
  • Absence of new onset neurological symptoms
  • Presence of fewer than ten intracranial lesions
  • Each lesion measures three centimeters or less
  • Life expectancy of greater than three months
  • Adequate organ and marrow function
  • Ability to understand and willingness to sign a written informed consent document

Who cannot take part

  • Major surgical procedure (including craniotomy and open brain biopsy) or significant traumatic injury within 14 days prior to registration
  • Receipt of a non-CNS minor surgical procedure (e.g. core biopsy or fine needle aspiration) within three days prior to registration
  • Serious non-healing wound, ulcer or bone fracture
  • History of allergic reactions attributed to monoclonal antibodies (mAb), compounds of similar chemical or biologic composition to Pembrolizumab
  • Clinically significant cardiovascular disease
  • Patients with uncontrolled intercurrent illness
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • Presence of oncogenic driver mutations
  • Measurable lesion located within 10mm of the optic chiasm or optic nerve, or within the brainstem
  • Known leptomeningeal involvement
  • Midline shift
  • Baseline inability to participate or complete neurocognitive testing

Where in United States

  • University of Kentucky/Markey Cancer CenterLexington, United States

About the trial

What the trial wants to find out

The goal of this study is to evaluate whether providing Pembrolizumab prolongs survival and preserves quality of life while minimizing side effects for patients with NSCLC with untreated asymptomatic brain metastasis.

The group in the trial

  • Pembrolizumab with standard of care chemotherapy treatmentTreatment being tested

    Patients will receive 200mg or 400mg of Pembrolizumab (standard of care dosing at the discretion of treating physician) over thirty minutes on day 1 every three or six weeks with standard of care chemotherapy treatment (carboplatin, pemetrexed, paclitaxel, nab-paclitaxel).

    Treatment: Pembrolizumab, Nab paclitaxel, Paclitaxel, Pemetrexed, and Carboplatin

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase II Investigation of Use of CNS Active Pembrolizumab and Chemotherapy for Asymptomatic Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)
Record updated
31 October 2025